1 / 1
Roflumilast(Daxas)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
ASTRAZENECA AB
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Daxas(Roflumilast) Instructions:Uses,Dosage, Side Effects
DALIRESP, with the active ingredient roflumilast, is an orally administered medication classified as a selective phosphodiesterase 4 (PDE4) inhibitor. By inhibiting PDE4, it increases intracellular cyclic AMP levels in lung cells, which is believed to mediate anti-inflammatory effects. It is not a bronchodilator and therefore does not provide immediate relief for acute breathing difficulties. The product is supplied as 250 mcg and 500 mcg film-coated tablets and is marketed by AstraZeneca Pharmaceuticals LP for a specific subset of COPD patients.
